Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer | Colorectal Cancer | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal CancerThe Canadian Cancer Trials Group CO.26 Study

Educational Objective
To learn the effect of combined immune checkpoint inhibition vs best supportive care in patients with advanced colorectal cancer.
1 Credit CME
Key Points

Question  Can combined immune checkpoint inhibition improve overall survival (OS) in patients with advanced refractory colorectal cancer (CRC)?

Findings  In this randomized phase 2 study with 180 patients randomized in a 2:1 ratio to tremelimumab and durvalumab plus best supportive care or best supportive care alone, the median OS was 6.6 months for durvalumab and tremelimumab and 4.1 months for best supportive care; correlative analysis revealed that patients with plasma tumor mutation burden (TMB) of 28 or more variants per megabase had the greatest OS benefit.

Meaning  Combined immune checkpoint inhibition may prolong OS in patients with advanced refractory CRC.

Abstract

Importance  Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H).

Objective  To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibition improved patient survival in metastatic refractory CRC.

Design, Setting, and Participants  A randomized phase 2 study was conducted in 27 cancer centers across Canada between August 2016 and June 2017, and data were analyzed on October 18, 2018. Eligible patients had histologically confirmed adenocarcinoma of the colon or rectum; received all available standard systemic therapies (fluoropyrimidines, oxaliplatin, irinotecan, and bevacizumab if appropriate; cetuximab or panitumumab if RAS wild-type tumors; regorafenib if available); were aged 18 years or older; had adequate organ function; had Eastern Cooperative Oncology Group performance status of 0 or 1, and measurable disease.

Interventions  We randomly assigned patients to receive either 75 mg of tremelimumab every 28 days for the first 4 cycles plus 1500 mg durvalumab every 28 days, or best supportive care alone (BSC) in a 2:1 ratio.

Main Outcomes and Measures  The primary end point was overall survival (OS) and a 2-sided P<.10 was considered statistically significant. Circulating cell-free DNA from baseline plasma was used to determine microsatellite instability (MSI) and tumor mutation burden (TMB).

Results  Of 180 patients enrolled (121 men [67.2%] and 59 women [32.8%]; median [range] age, 65 [36-87] years), 179 were treated. With a median follow-up of 15.2 months, the median OS was 6.6 months for durvalumab and tremelimumab and 4.1 months for BSC (hazard ratio [HR], 0.72; 90% CI, 0.54-0.97; P = .07). Progression-free survival was 1.8 months and 1.9 months respectively (HR, 1.01; 90% CI, 0.76-1.34). Grade 3 or 4 adverse events were significantly more frequent with immunotherapy (75 [64%] patients in the treatment group had at least 1 grade 3 or higher adverse event vs 12 [20%] in the BSC group). Circulating cell-free DNA analysis was successful in 168 of 169 patients with available samples. In patients who were microsatellite stable (MSS), OS was significantly improved with durvalumab and tremelimumab (HR, 0.66; 90% CI, 0.49-0.89; P = .02). Patients who were MSS with plasma TMB of 28 variants per megabase or more (21% of MSS patients) had the greatest OS benefit (HR, 0.34; 90% CI, 0.18-0.63; P = .004).

Conclusions and Relevance  This phase 2 study suggests that combined immune checkpoint inhibition with durvalumab plus tremelimumab may be associated with prolonged OS in patients with advanced refractory CRC. Elevated plasma TMB may select patients most likely to benefit from durvalumab and tremelimumab. Further confirmation studies are warranted.

Trial Registration  ClinicalTrials.gov Identifier: NCT02870920

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Eric X. Chen, MD, PhD, Princess Margaret Cancer Center, 700 University Ave, Rm 7-824, Toronto, ON M5G 1X6 Canada (eric.chen@uhn.ca).

Accepted for Publication: March 2, 2020.

Published Online: May 7, 2020. doi:10.1001/jamaoncol.2020.0910

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Chen EX et al. JAMA Oncology.

Author Contributions: Drs Chen and O’Callaghan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Chen, Jonker, Loree, Ahmad, Kavan, Tu, O'Callaghan.

Acquisition, analysis, or interpretation of data: Chen, Jonker, Loree, Kennecke, Berry, Couture, Goffin, Kavan, Harb, Colwell, Samimi, Samson, Abbas, Aucoin, Aubin, Koski, Wei, Magoski, Tu, O'Callaghan.

Drafting of the manuscript: Chen, Jonker, Loree, Ahmad, Kavan, Abbas.

Critical revision of the manuscript for important intellectual content: Chen, Jonker, Loree, Kennecke, Berry, Couture, Goffin, Kavan, Harb, Colwell, Samimi, Samson, Aucoin, Aubin, Koski, Wei, Magoski, Tu, O'Callaghan.

Statistical analysis: Loree, Tu, O'Callaghan.

Obtained funding: Jonker, Aucoin, O'Callaghan.

Administrative, technical, or material support: Chen, Jonker, Loree, Kennecke, Couture, Goffin, Samimi, Aucoin, Aubin, Wei, Magoski, O'Callaghan.

Supervision: Jonker, Ahmad, Kavan, Samimi, Abbas, Aubin, Koski, O'Callaghan.

Conflict of Interest Disclosures: Dr Chen participated in clinical trials sponsored by Merck, BMS, Boston Biomedical, AZ, and received research support (drugs only) from AZ. Dr Chen received honoraria from Eisai and Taiho. Dr Loree received research support from Ipsen and honoraria from Ipsen, Amgen, Bayer, Novartis, and Taiho. Dr Samson received honorarium from Taiho. Dr Goffin received honoraria from Merck and Amgen and nonfinancial support from AZ. Dr Samimi received honoraria from Amgen, Celgene, Ipsen, Apobiologix, Eisai, Taiho, and Roche. Dr Aubin received honoraria from Taiho, Shire, Amgen, BMS, and Celgene, and participated in clinical trials sponsored by Merck and BMS. Dr Aucoin received honoraria from AZ, Roche, BMS, Amgen, Takeda, Pfizer, Taiho, Celgene. Dr Wei received honoraria from Shire and Celgene, and nonfinancial support from Bayer. All other authors declared no competing interests.

Data Sharing Statement: See Supplement 3.

Funding/Support: AstraZeneca provided durvalumab and tremelimumab and contributed partial funding for this study. The Canadian Cancer Trials Group (CCTG) is funded by the Canadian Cancer Society.

Role of the Funder/Sponsor: AstraZeneca was consulted on design of the study, and reviewed a draft of the manuscript. It played no role in conduct of the study; collection, management, analysis, and interpretation of the data; preparation, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: Presented at ASCO GI Symposium, January 19, 2019, San Francisco, California; and at ASCO Annual Meeting, June 3, 2019, Chicago, Illinois.

References
1.
Bray  F , Ferlay  J , Soerjomataram  I , Siegel  RL , Torre  LA , Jemal  A .  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.   CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 PubMedGoogle ScholarCrossref
2.
Siegel  RL , Miller  KD , Jemal  A .  Cancer statistics, 2019.   CA Cancer J Clin. 2019;69(1):7-34. doi:10.3322/caac.21551 PubMedGoogle ScholarCrossref
3.
Venook  AP , Niedzwiecki  D , Lenz  HJ ,  et al.  Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial.   JAMA. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105 PubMedGoogle ScholarCrossref
4.
Stintzing  S , Modest  DP , Rossius  L ,  et al; FIRE-3 investigators.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.   Lancet Oncol. 2016;17(10):1426-1434. doi:10.1016/S1470-2045(16)30269-8 PubMedGoogle ScholarCrossref
5.
Grothey  A , Van Cutsem  E , Sobrero  A ,  et al; CORRECT Study Group.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.   Lancet. 2013;381(9863):303-312. doi:10.1016/S0140-6736(12)61900-X PubMedGoogle ScholarCrossref
6.
Mayer  RJ , Van Cutsem  E , Falcone  A ,  et al; RECOURSE Study Group.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.   N Engl J Med. 2015;372(20):1909-1919. doi:10.1056/NEJMoa1414325 PubMedGoogle ScholarCrossref
7.
Le  DT , Uram  JN , Wang  H ,  et al.  PD-1 blockade in tumors with mismatch-repair deficiency.   N Engl J Med. 2015;372(26):2509-2520. doi:10.1056/NEJMoa1500596 PubMedGoogle ScholarCrossref
8.
Le  DT , Durham  JN , Smith  KN ,  et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.   Science. 2017;357(6349):409-413. doi:10.1126/science.aan6733 PubMedGoogle ScholarCrossref
9.
Overman  MJ , McDermott  R , Leach  JL ,  et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.   Lancet Oncol. 2017;18(9):1182-1191. doi:10.1016/S1470-2045(17)30422-9 PubMedGoogle ScholarCrossref
10.
Overman  MJ , Lonardi  S , Wong  KYM ,  et al.  Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.   J Clin Oncol. 2018;36(8):773-779. doi:10.1200/JCO.2017.76.9901 PubMedGoogle ScholarCrossref
11.
Antonia  S , Goldberg  SB , Balmanoukian  A ,  et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.   Lancet Oncol. 2016;17(3):299-308. doi:10.1016/S1470-2045(15)00544-6 PubMedGoogle ScholarCrossref
12.
Eisenhauer  EA , Therasse  P , Bogaerts  J ,  et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).   Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026 PubMedGoogle ScholarCrossref
13.
Common Terminology Criteria for Adverse Events. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40. Accessed February 28, 2020.
14.
Helman  E , Artieri  C , Vowles  JV ,  et al.  Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research.   Cancer Res. 2018;78(13)(suppl−Abstr 5603):5603.Google Scholar
15.
Quinn  K , Helman  E , Nance  T , Artieri  C , Yen  J , Zhao  J ,  et al.  Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels.   Ann Oncol. 2018;29(suppl 8):131P. doi:10.1093/annonc/mdy269.129Google ScholarCrossref
16.
Artyomenko  A , Barbacioru  C , Chudova  D , Helman  E , Sikora  M , Artieri  C ,  et al.  Microsatellite instability detection by targeted sequencing of cell-free DNA.   Ann Oncol. 2018;29(suppl 8):1190. doi:10.1093/annonc/mdy288.063Google ScholarCrossref
17.
Fayers  P , Bottomley  A ; EORTC Quality of Life Group; Quality of Life Unit; European Organisation for Research and Treatment of Cancer.  Quality of life research within the EORTC-the EORTC QLQ-C30.   Eur J Cancer. 2002;38(suppl 4):S125-S133. doi:10.1016/S0959-8049(01)00448-8 PubMedGoogle ScholarCrossref
18.
Loree  JM , Jonker  DJ , Feilotter  H , Kennecke  HF , Brohawn  PZ , Banks  K ,  et al.  Impact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26.   Ann Oncol. 2019;30(Suppl 5):200. doi:10.1093/annonc/mdz246.006Google ScholarCrossref
19.
Innocenti  F , Ou  FS , Qu  X ,  et al.  Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome.   J Clin Oncol. 2019;37(14):1217-1227. doi:10.1200/JCO.18.01798 PubMedGoogle ScholarCrossref
20.
George  TJ , Frampton  GM , Sun  J ,  et al.  Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.   J Clin Oncol. 2016;34(15):3587. doi:10.1200/JCO.2016.34.15_suppl.3587 Google ScholarCrossref
21.
Riaz  N , Havel  JJ , Makarov  V ,  et al.  Tumor and microenvironment evolution during immunotherapy with nivolumab.   Cell. 2017;171(4):934-949.e16. doi:10.1016/j.cell.2017.09.028 PubMedGoogle ScholarCrossref
22.
Russo  M , Crisafulli  G , Sogari  A ,  et al.  Adaptive mutability of colorectal cancers in response to targeted therapies.   Science. 2019;366(6472):1473-1480. doi:10.1126/science.aav4474 PubMedGoogle ScholarCrossref
23.
Powles  T , Durán  I , van der Heijden  MS ,  et al.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.   Lancet. 2018;391(10122):748-757. doi:10.1016/S0140-6736(17)33297-X PubMedGoogle ScholarCrossref
24.
Hellmann  MD , Nathanson  T , Rizvi  H ,  et al.  Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer.   Cancer Cell. 2018;33(5):843-852.e4. doi:10.1016/j.ccell.2018.03.018 PubMedGoogle ScholarCrossref
25.
Hellmann  MD , Ciuleanu  TE , Pluzanski  A ,  et al.  Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.   N Engl J Med. 2018;378(22):2093-2104. doi:10.1056/NEJMoa1801946 PubMedGoogle ScholarCrossref
26.
Samstein  RM , Lee  CH , Shoushtari  AN ,  et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types.   Nat Genet. 2019;51(2):202-206. doi:10.1038/s41588-018-0312-8 PubMedGoogle ScholarCrossref
27.
Schrock  AB , Ouyang  C , Sandhu  J ,  et al.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.   Ann Oncol. 2019;30(7):1096-1103. doi:10.1093/annonc/mdz134 PubMedGoogle ScholarCrossref
28.
Mandal  R , Samstein  RM , Lee  KW ,  et al.  Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.   Science. 2019;364(6439):485-491. doi:10.1126/science.aau0447 PubMedGoogle ScholarCrossref
29.
Peters  S , Cho  BC , Reinmuth  N ,  et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. In: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, 2019; Altanta. Abstract: CT074.
30.
Fukuoka  S , Hara  H , Takahashi  N ,  et al.  Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).   J Clin Oncol. 2019;37(15):2522. doi:10.1200/JCO.2019.37.15_suppl.2522 Google ScholarCrossref
31.
Mettu  NB , Twohy  E , Ou  FS , Halfdanarson  TR , Lenz  HJ , Breakstone  R ,  et al.  BACCI: a phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): an ACCRU network study.   Ann Oncol. 2019;30(Suppl 5):533. doi:10.1093/annonc/mdz246.011Google ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close